NCT07205523Recruiting
High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)
High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT): A Prospective Real-World Cohort Study in the Qinghai-Tibet Plateau
Source: ClinicalTrials.gov · Last updated 3 Oct 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT) study is the first prospective real-world cohort of hematologic diseases and transplantation in the Qinghai-Tibet Plateau. Patients undergoing hematopoietic stem cell transplantation (HSCT) at Qinghai University Affiliated Hospital, together with their donors, are systematically enrolled. The registry collects demographic, diagnostic, treatment, prognosis, and medical expense information, as well as biospecimens for future analyses. Historical data are incorporated, and prospective data collection is ongoing with long-term follow-up planned. The registry is designed as a sustainable research infrastructure to provide comprehensive data on disease incidence, treatment patterns, outcomes, and resource utilization in a high-altitude setting.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 1000 (estimated)
- First submitted
- 12 Sept 2025
- Start date
- 1 Sept 2023
- Primary completion date
- 31 Dec 2060
- Lead sponsor
- Yigeng Cao,MD,PhD
- Diseases
- Haemophilia, Myelodysplastic syndromes, Multiple myeloma, Acute myeloid leukemia, Childhood cancers
- NCT number
- NCT07205523
What you commit to
- Study type: Observational
- Planned participants: 1000
- From 1 Sept 2023 to the primary completion date, 31 Dec 2060
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Any condition judged by investigators to jeopardize safety or compliance.
Other
- Inability to provide long-term follow-up data due to severe comorbidities or logistical reasons.
- Substance abuse compromising adherence.
Who the study is looking for
- Patients diagnosed with hematologic diseases who are admitted to the HSCT center of Qinghai University Affiliated Hospital on or after September 1, 2023.
- Planned or actual hematopoietic stem cell transplantation (HSCT).
- Provision of signed informed consent.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Affiliated Hospital of Qinghai University Coordinator of this site? Confirm its status | Xining | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.